Skip to main content


Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (AD) (THC-AD)

Alzheimer's disease, Psychiatric disorders
All genders
person-wave 60-95
Recruiting now
More information  


Principal Investigator: Brent P. Forester MD, MSc

This research study is a 3-week clinical trial of dronabinol, a synthetic form of tetrahydrocannabinol (THC). This study is being done to determine if dronabinol is a safe and effective treatment for agitation symptoms related to Alzheimer’s disease. This study will compare dronabinol to a placebo.

Study details

Inclusion Criteria
  • - Must speak English and/or Spanish (includes reading, writing, and speech)
  • - Have a diagnosis of Dementia due to Alzheimer's disease
  • - Have agitation symptoms defined clinically
Exclusion Criteria
  • - Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematological disease
  • _ Seizure disorder
  • - Current prescription of lithium
Study Requirements

Participants will be given an investigational drug and asked to come for 5 study visits. Participants will complete screening questionaries at the first study visit before receiving the investigational drug. Participants will complete more questionnaires at later study visits. Participants will also receive a physical examination, neurological examination, electrocardiogram (ECG), and give a total of 2 blood samples. We expect the total duration of this research study to be 3 weeks.

Jump back to top